Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase

Main Article Content

Elke Weisshaar
Thomas Sciascia
Sonja Stander


Prurigo Nodularis, Nalbuphine, Opioid Agonist/Antagonist, Efficacy, Safety


Abstract not available.


1. Ständer HF, et al. J Am Acad Dermatol. 2020;82:460 460-68.

2. Tsianakas A, et al. Curr Probl Dermatol. 2016;50:94 94-101.

3. Weisshaar E, et al. Acta Derm Venereol . 2019;99:469 469-506.

4. Ständer S, et al. Itch. 2020; submitted.

5. Kjellberg F, Tramèr MR. Eur J Anaesthesiol . 2001;18:346 346-57.

6. Mathur VS, et al. Am J Nephrol. 2017;46:450 450-8

Most read articles by the same author(s)